Steer clear of anti-HER2 cancer therapies while expecting.

Published Date: 02 Dec 2023

A higher risk of severe adverse outcomes for the fetus or newborn exists for women with HER2-positive breast cancer who receive HER2-targeted therapies during pregnancy, according to new research.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Targeted radiation therapy shows near-complete response in rare sarcoma patients

2.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

3.

Germline Profiling May Improve Risk Stratification in t-MNs

4.

Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.

5.

Scientists call into question safety of potential new anticancer treatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot